REACHING TO IMPROVE THE LIVES OF
patients with cancer
MBrace develops new treatments for cancer patients based on the SPARTA technology pioneered by our founders.
MBrace Therapeutics emerges from stealth mode with $85M.
Read the details in our latest press release.
Our Approach
Our robust antibody discovery methodology SPARTA overcomes several rate-limiting challenges to generate human antibodies amenable to rapid translation into clinical applications.
In Development
We’re developing ADCs against two novel cancer targets using human antibodies selected from SPARTA methodology.